Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -73.13% | -41.61% | -9.05% | -68.46% | -76.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -73.13% | -41.61% | -9.05% | -68.46% | -76.54% |
| Cost of Revenue | 6.28% | 42.70% | -33.76% | -11.39% | -27.97% |
| Gross Profit | -9.52% | -49.60% | 35.07% | 7.73% | 21.32% |
| SG&A Expenses | -4.19% | 11.65% | -12.86% | -24.21% | -9.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.73% | 35.99% | -28.91% | -15.10% | -24.19% |
| Operating Income | -6.08% | -40.88% | 29.71% | 12.71% | 18.64% |
| Income Before Tax | 75.83% | -64.24% | -398.63% | 223.80% | -194.12% |
| Income Tax Expenses | 11.11% | -38.46% | -2.12% | 79.17% | 190.00% |
| Earnings from Continuing Operations | 75.80% | -63.75% | -413.44% | 223.59% | -194.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.80% | -63.75% | -413.44% | 223.59% | -194.53% |
| EBIT | -6.08% | -40.88% | 29.71% | 12.71% | 18.64% |
| EBITDA | -6.08% | -41.53% | 30.01% | 12.47% | 18.32% |
| EPS Basic | 85.36% | 0.95% | -289.48% | 191.81% | -137.66% |
| Normalized Basic EPS | 85.38% | 0.66% | -280.51% | 191.96% | -143.65% |
| EPS Diluted | 85.34% | 0.95% | -289.48% | 62.20% | -137.66% |
| Normalized Diluted EPS | 85.38% | 0.66% | -280.75% | 188.78% | -143.65% |
| Average Basic Shares Outstanding | 65.29% | 65.32% | 65.41% | 34.62% | 23.93% |
| Average Diluted Shares Outstanding | 65.29% | 65.32% | 65.20% | 39.44% | 23.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |